NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

Filana Therapeutics, Inc. (FLNA) Stock Analysis

Filana Therapeutics, Inc. (FLNA) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

FLNA

$0.66

−$0.03 (−4.24%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare FLNA with… →

FLNA Key Statistics

As of Oct 21, 2026
Trading
Open
$0.69
Previous Close
$0.69
Day's Range
0.65–0.71
52-Week Range
0.65–4.02
Volume
305.72K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.66
Valuation
Market Cap
$31.85M
P/E Ratio
unprofitable
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
1.62
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.86
Financials (FY)
Revenue (FY)
$0.00
Net Income (FY)
−$90.97M
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
48.31M
1-Year Return
−83.43%
Dividend and dates
Earnings Date
October 29, 2026estimated
Avg Volume
2.02M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, FLNA closed at $0.66, −83.43% over 1 year.

Filana Therapeutics, Inc. (FLNA) has a market capitalization of $31.85M.

In fiscal 2025, FLNA reported revenue of $0.00.

FLNA Stock Return by Calendar Year

Filana Therapeutics, Inc. (FLNA) 10-year return: what $10,000 became

1 year
$10,000 $1,657
−83.43%
5 years
$10,000 $142
−98.58%
10 years
$10,000 $1,256
−87.44%

If you had invested $10,000 in Filana Therapeutics, Inc. (FLNA) 10 years ago, at the close on October 21, 2016, it would have been worth $1,256 at the close on October 21, 2026: −87.44% in total, −18.74% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−66.70%
2025−16.10%
2024−89.52%
2023−23.80%
2022−32.40%
2021+540.76%
2020+31.15%
2019+511.76%
2018−78.75%
2017+0.25%
2016 (partial year)−78.16%

As of October 21, 2026.

FLNA Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$0.00−$90.97M—
2024$0.00−$24.34M—
2023$0.00−$97.22M—
2022$0.00−$76.25M—
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$0.00—−$96.13M−$90.97M—
2024$0.00—−$142.28M−$24.34M—
2023$0.00—−$107.33M−$97.22M—
2022$0.00—−$81.48M−$76.25M—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

Recent News

All 7 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Filana Therapeutics, Inc. (FLNA) carries a market capitalisation of $31.85M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 17.

FLNA last closed at $0.66 on October 21, 2026. That is −$0.03 (−4.24%) against the previous close. The 52-week range on file runs from $0.65 to $4.02. The latest close sits 1.34% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $90.97M. Earnings per share on a trailing basis come to −0.86.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The PEG ratio, which sets the P/E against expected earnings growth, reads 1.62.

Over the trailing twelve months the total return is −83.43%. Across 10 years the annualized return works out at −18.74%. The reported beta is −0.66. Annualized volatility over the trailing 10 years is 153.67%.

Growth & Income

No dividend is on file for FLNA.

2026 is still running; the total return is −66.70% year to date. Across the complete calendar years on file, 2021 returned +540.76% and 2024 returned −89.52%. Of the 9 complete calendar years on file, 4 finished higher.

Peer Comparison

Filana Therapeutics, Inc. (FLNA) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Filana Therapeutics, Inc. FLNA $31.85M —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. Filana Therapeutics, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is in Phase 3 clinical trial to treat Alzheimer's disease; and investigational diagnostic product candidate is SavaDx, an early-stage program focused on detecting the presence of Alzheimer's disease from a small sample of blood. The company was formerly known as Cassava Sciences, Inc. and changed its name to Filana Therapeutics, Inc. in March 2026. The company was incorporated in 1998 and is based in Austin, Texas.

Visit website →